Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Pharmacotherapy for adult asthma has two main goals: address underlying airway inflammation and promote bronchodilation. Two types of therapy are used to achieve these goals—maintenance therapy (e.g., a LABA/ICS, such as GSK’s Advair or AstraZeneca’s Symbicort) and rescue therapy (e.g., a SABA, such as albuterol)—and most adult asthma patients receive more than one drug to treat their condition. Although multiple well-established agents are available for both maintenance and rescue treatment, in the past few years, the adult asthma treatment landscape has witnessed the approval of the first branded-generic LABA/ICS FDC (i.e., Teva’s AirDuo and its generic), the first LAMA (i.e., Boehringer-Ingelheim’s Spiriva), and several novel biologics (e.g., GSK’s Nucala, Teva’s Cinqair). The availability of these agents has expanded physicians’ treatment arsenal and fueled increasing competition in the asthma therapy market.
Key Drugs Covered
Key Analysis Provided
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Already a Client? Log in to access this report.
Shubhendu Ghosh, is a Business Insights Analyst on the Immune and Inflammatory Disorders team at Decision Resources Group, with a primary focus on asthma. Prior to joining DRG, Shubhendu was an Associate Editor at Nature Structural & Molecular Biology and a Copy Editor at Nature Medicine. He was also a Scientific and Developmental Editor at Nature Research Editing Service. Shubhendu received his in Biomedical Sciences from the University of Massachusetts Medical School after completing a B. Sc. in Microbiology from Delhi University and an M. Sc. In Biotechnology from Madurai Kamaraj University.